Spectrum in-licenses novel GCSF drug from Hanmi Pharma

1 February 2012

USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) has entered into a co-development and commercialization agreement with South Korean company Hanmi Pharmaceutical for SPI-2012 (formerly known as LAPS-GCSF), a drug for the treatment of chemotherapy induced neutropenia based on Hanmi’s proprietary LAPSCOVERY Technology. Financial terms of the deal were not revealed.

In a US Phase I study in healthy volunteers, SPI-2012 demonstrated activity similar to Neulasta (pegfilgrastim) at one-third of the dose, according to Spectrum, which expects to initiate Phase II trials in collaboration with Hanmi in 2012. If SPI-2012 is ultimately commercialized, Spectrum will own worldwide rights except for Korea, China, and Japan.

Drug would enter $5 billion GCSF-related drugs market

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK